Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2022)
11 slides from Immuron's shareholder meeting presentation, Nov 21, 2022
Slide 1: AGM Presentation
For personal use only AGM PRESENTATION 21 NOVEMBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT For personal use only Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance”
Slide 3: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company • Two commercially available oral immunotherapeutic pr
Slide 4: Company Highlights: Commercial Assets and US DoD Collaboration
COMPANY HIGHLIGHTS For personal use only Our Flagship Commercial Assets – Once Again Generating Revenue o Global sales increased by 425% in FY22 to AU $765k, compared to AU $146k in FY21 o Global sales to end October increased by 343% in the FY22 to AU$500k, compared to AU $113k LY Collaborations wi
Slide 5: Company Highlights: Naval Medical Research Center and USU Trial
COMPANY HIGHLIGHTS US Naval Medical Research Center – Campylobacter & ETEC PROJECT o New Therapeutic in Clinical Development for Treatment of moderate to severe For personal use only Campylobacteriosis and Infectious diarrhea caused by ETEC pathogens o IND Clinical Hold – July 2022 o Contact execute
Slide 6: Company Highlights: IMM-529 C. difficile Development
COMPANY HIGHLIGHTS IMM-529 Clinical Development for Treatment of C. difficile Infections For personal use only o Opportunity Assessment Completed o C. difficile infection (CDI) affects just over ~400,000 people in the US annually o Sizable number of patients who experience at least one recurrence (~
Slide 7: Business Positioned for Organic Growth and New M&A Strategy
BUSINESS POSITIONED FOR ORGANIC GROWTH AND NEW M&A STRATEGY Australia USA Canada For personal use only Retail Pharmacy M&A Strategy B2B • By pursuing growth through M&A of a fragmented market, IMC believes that it E-commerce will be able to increase market geographies, sales channels and penetration
Slide 8: Thank You
For personal use only THANK YOU 8
Slide 9: Addressable Market & Industry Overview
ADDRESSABLE MARKET & INDUSTRY OVERVIEW For personal use only Immuron’s products are a subset of the global digestive health market, which a multi-billion-dollar market* ~$15b+ Billion Dollar Market Ateria strategic investment establishes Immuron’s position in the large and growing IBS market which i
Slide 10: Immuron's Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT For personal use only Lumanity* Opportunity Assessment for IMM-124E Lumanity Opportunity Assessment for IMM-529 • Immuron’s development of IMM-124E (hyperimmune bovine • Infectious disease experts reacted favorably to the IMM-529 MOA, and colostru
Slide 11: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: For personal use only to 90% of volunteers 10.3109/00365521.2011.574726 Travelan as a broad Spe